Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Notes Payables (2016 - 2017)

Historic Notes Payables for Gyre Therapeutics (GYRE) over the last 3 years, with Q4 2017 value amounting to $5.1 million.

  • Gyre Therapeutics' Notes Payables fell 7379.27% to $5.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $5.1 million, marking a year-over-year decrease of 7379.27%. This contributed to the annual value of $5.1 million for FY2017, which is 7379.27% down from last year.
  • Gyre Therapeutics' Notes Payables amounted to $5.1 million in Q4 2017, which was down 7379.27% from $5.5 million recorded in Q3 2017.
  • Gyre Therapeutics' 5-year Notes Payables high stood at $34.8 million for Q3 2015, and its period low was $5.1 million during Q4 2017.
  • In the last 3 years, Gyre Therapeutics' Notes Payables had a median value of $24.5 million in 2016 and averaged $20.8 million.
  • In the last 5 years, Gyre Therapeutics' Notes Payables plummeted by 1468.87% in 2016 and then tumbled by 8150.13% in 2017.
  • Over the past 3 years, Gyre Therapeutics' Notes Payables (Quarter) stood at $33.7 million in 2015, then tumbled by 42.5% to $19.4 million in 2016, then crashed by 73.79% to $5.1 million in 2017.
  • Its Notes Payables was $5.1 million in Q4 2017, compared to $5.5 million in Q3 2017 and $5.8 million in Q2 2017.